Recent Updates
Recently added Catalysts
WVE Negative Sentiment

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Key Takeaway: Johnson Fistel, PLLP is investigating potential claims for investors of Wave Life Sciences Ltd. after the company disclosed interim Phase 1 clinical data for WVE-007. The data revealed only modest reductions in body weight, which led to a significant stock price decline on March 26, 2026. The firm is examining whether the company's executive officers complied with federal securities laws amidst these losses for investors. Individuals who purchased securities in Wave Life Sciences and suffered losses are encouraged to join the investigation.
Price reaction · baseline $12.3 (2026-03-25 close) · hit after-hours · 1 other WVE headline(s) in the window, move may be shared
day 0 close
-49.6%
day 1
-48.3%
day 3
-41.1%

Market Sentiment Analysis

CONCERNS & RISKS

  • Wave Life Sciences announced only modest reductions in body weight in their Phase 1 clinical data for WVE-007.
  • The trial involved a patient population with a lower baseline body mass index, which is atypical for later-stage obesity studies.
  • The company's stock price declined significantly following the announcement of the interim clinical data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave Life Sciences’ executive officers and whether investor losses may be recovered under federal securities laws.
What if I purchased Wave Life Sciences securities?
If you purchased Wave Life Sciences securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On March 26, 2026, Wave Life Sciences announced interim Phase 1 clinical data for WVE-007. The Company reported only modest reductions in body weight despite reductions in certain fat-related measures. The Company also disclosed that the trial involved a patient population with a lower baseline body mass index than is typical for later-stage obesity studies.
Following these disclosures, Wave Life Sciences’ stock price declined significantly on March 26, 2026.
In light of this disclosure, Johnson Fistel is investigating whether Wave Life Sciences complied with the federal securities laws. If you suffered losses from your investment in Wave Life Sciences stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
James Baker, Investor Relations – or – Frank J. Johnson, Esq.

Frequently Asked Questions

What is the focus of the Johnson Fistel investigation?

The investigation focuses on whether Wave Life Sciences’ executives caused investor losses under federal securities laws.

What triggered Wave Life Sciences' stock price decline?

The stock price dropped after Wave Life Sciences announced modest Phase 1 clinical data for WVE-007.

How can I participate in the investigation?

If you suffered losses from investing in Wave Life Sciences, you can join the investigation for free.

What services does Johnson Fistel offer?

Johnson Fistel represents investors in securities class action lawsuits and derivative cases.

Is there a cost to join the investigation?

No, there is no cost or obligation to participate in the investigation.

Last updated: Mar 26, 2026